2021
DOI: 10.4322/acr.2021.304
|View full text |Cite
|
Sign up to set email alerts
|

The vasa vasorum of the large pulmonary vessels are involved in COVID-19

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 6 publications
1
2
0
Order By: Relevance
“…Many parallels were drawn between TA‐TMA after HSCT and systemic TMA from COVID in non‐HSCT patients. Autopsy cases from COVID patients demonstrated C5b‐9 and C4d deposits in a pattern and severity similar to reports in TA‐TMA after HSCT 106–108 . Complement effector functions that lead to SARS‐CoV‐2‐induced TMA and acute lung injury are well‐described.…”
Section: Additional Considerations For Ta‐tma Therapy and Complement ...supporting
confidence: 71%
See 1 more Smart Citation
“…Many parallels were drawn between TA‐TMA after HSCT and systemic TMA from COVID in non‐HSCT patients. Autopsy cases from COVID patients demonstrated C5b‐9 and C4d deposits in a pattern and severity similar to reports in TA‐TMA after HSCT 106–108 . Complement effector functions that lead to SARS‐CoV‐2‐induced TMA and acute lung injury are well‐described.…”
Section: Additional Considerations For Ta‐tma Therapy and Complement ...supporting
confidence: 71%
“…Autopsy cases from COVID patients demonstrated C5b-9 and C4d deposits in a pattern and severity similar to reports in TA-TMA after HSCT. [106][107][108] Complement effector functions that lead to SARS-CoV- With novel cellular therapies like chimeric antigen receptor T-cells (CARTs) and VSTs on the rise, we are bound to induce cytokine storms with the potential to injure the endothelium in different organs. 94 While cellular therapy-induced cytokine release syndrome (CRS) may respond to IL-6 blockade, more complicated syndromes like immune effector cell-associated neurotoxicity syndrome (ICANS) do not have effective interventions.…”
Section: C5 and Lectin Pathway Inhibitorsmentioning
confidence: 99%
“…The recent data about the worsening of the course of atherosclerosis in patients with COVID-19 infection, the presence of inflammation of arterial wall both in COVID-19 and atherosclerosis, the reports of higher frequencies of cardiovascular complications in COVID-19 and post-COVID-19 disorders, and the importance of Vasa vasorum in atherogenesis all call for the investigation of pathomorphology of vessel walls in these diseases [ 7 , 18 ].…”
Section: Introductionmentioning
confidence: 99%